Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
Active, not recruiting · Phase 1 · NCT05618028
Conditions: Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, B Cell Malignancies, Non-Hodgkin's Lymphoma
At a glance
- Research payments reported, 2025
- $478,874
- U.S. investigators named
- 12
- Sites paid
- 15
- Planned or actual enrollment
- 78
About the trial
- Sponsor
- AbbVie
- Tested
- ABBV-525 (drug)
- Dates
- Started 2023-04-04; completion 2029-07
- Results posted
- Not yet
B-cell malignancies are a group of cancers of B lymphocytes, a type of white blood cell responsible for fighting infections. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-525 as a monotherapy. ABBV-525 is an investigational drug being developed for the treatment of B-Cell Malignancies. Study doctors put the participants in groups called treatment arms. Participants will receive ABBV-525 at different doses. Approximately 150 adult participants will be enrolled in the study across sites worldwide. In part 1 (dose escalation), participants will receive escalating oral doses of ABBV-525. In part 2 (dose optimization), participan…
From ClinicalTrials.gov, last updated 2026-05-04. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $478,874 in research payments for this study in 2025 (60 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Herbert A. Eradat, M.D., M.S. Internal Medicine · Los Angeles, CA
- Shalin K. Kothari, MD Hematology & Oncology · New Haven, CT
- Jacqueline Barrientos, M.D. Hematology & Oncology · Miami Beach, FL
- Rita Assi, MD Hematology & Oncology · Indianapolis, IN
- Sunil Babu, M.D. Medical Oncology · Fort Wayne, IN
- Andrew L. Sochacki, M.D. Hematology & Oncology · Grand Rapids, MI
- Ryan W. Jacobs, MD Hematology · Charlotte, NC
- Meghan C. Thompson, MD Hematology & Oncology · New York, NY
- Zulfa Omer, MD Hematology & Oncology · Cincinnati, OH
- Jan A. Burger, M.D. Internal Medicine · Houston, TX
- Daniel A. Ermann, MD Hematology · Salt Lake City, UT
- Jorge M. Chaves, M.D. Hematology & Oncology · Tacoma, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Carolinas Medical Center-Northeast, NC $122,420
- Memorial Sloan Kettering Cancer Center $83,476
- University of Utah Hospital and Clinics, UT $78,948
- Start Midwest LLC $76,649
- Exigent Research LLC $24,867
- Memorial Sloankettering Cancer Center $23,803
- Mount Sinai Medical Center of Florida, Inc, FL $17,075
- Indiana University $16,210
- Ut MD Anderson Cancer Center $11,735
- Resnick Neuropsychiatric Hospital at UCLA, CA $10,222
- $6,280
- University of Cincinnati $5,750
- Atrium Health Union, NC $550
- Indiana University Health Center $296
- Yale School of Medicine $296
- Ronald Reagan UCLA Medical Center, CA $296
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.